Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study.
Research output: Contribution to journal › Article
Chronic migraine (CM) is a type of chronic daily headache. CM presents a challenge to primary care physicians and neurologists. Any new treatment showing efficiency would therefore be of great importance. Atenolol together with other beta-blockers is a first-line choice in episodic migraine prophylaxis. Clinical findings support the efficacy of atenolol in doses of 50 to 200 mg/day.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Issue number||Sep 22|
|Publication status||Published - 2013|
No data available